The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Blood-based tools to reduce bone marrow biopsies in multiple myeloma
Luca Bertamini, MD, Erasmus MC, Rotterdam, Netherlands, discusses the potential of blood-based tools to reduce reliance on bone marrow biopsies for multiple myeloma monitoring. He highlights the potential of combining circulating tumor cells (CTCs), circulating DNA (ctDNA) and M-protein assessment, while noting that further research is needed. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, I think that blood means a lot. So in the blood we have the cells, in the blood we have DNA, in the blood we have the M protein. So I think the blood is a very rich source. And I think that with the development of more sensitive techniques, I can imagine that combining this different type of way of looking at the tumor, looking at the cells, DNA, some mutations, and looking at the M protein, potentially blood will be superior or at least similar to the bone marrow...
Well, I think that blood means a lot. So in the blood we have the cells, in the blood we have DNA, in the blood we have the M protein. So I think the blood is a very rich source. And I think that with the development of more sensitive techniques, I can imagine that combining this different type of way of looking at the tumor, looking at the cells, DNA, some mutations, and looking at the M protein, potentially blood will be superior or at least similar to the bone marrow. So I think it’s a matter of time. It could be that in five years we’re seeing each other here and looking just at CTC-MRD, but I think we need still to do a lot of research to get there.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
